Abstract
In this report, we demonstrate that B7-H1, a B7 family molecule implicated in tumor immune evasion, is constitutively expressed on 66% of freshly isolated squamous cell carcinomas of the head and neck (SCCHN). To define the potential impact of tumor-associated B7-H1 on immunotherapy, the B7-H1-negative mouse SCC line, SCCVII, was transfected to express B7-H1. Although all of the animals succumbed to B7-H1/SCCVII tumors even after adoptive T-cell immunotherapy, the infusion of B7-H1 blocking monoclonal antibody with activated T cells cured 60% of animals. These data support B7-H1 blockade as a new approach to enhance the efficacy of T-cell immunotherapy.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Animals
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / pharmacology
-
Antigens, CD
-
B7-1 Antigen / biosynthesis
-
B7-1 Antigen / genetics
-
B7-1 Antigen / immunology*
-
B7-H1 Antigen
-
Blood Proteins*
-
Carcinoma, Squamous Cell / genetics
-
Carcinoma, Squamous Cell / immunology
-
Carcinoma, Squamous Cell / therapy*
-
Cell Line, Tumor
-
Head and Neck Neoplasms / immunology*
-
Head and Neck Neoplasms / therapy*
-
Humans
-
Immunotherapy, Adoptive / methods*
-
Lymphocyte Activation
-
Membrane Glycoproteins
-
Mice
-
Mice, Inbred C3H
-
Peptides*
-
T-Lymphocytes / immunology
-
Transfection
Substances
-
Antibodies, Monoclonal
-
Antigens, CD
-
B7-1 Antigen
-
B7-H1 Antigen
-
Blood Proteins
-
CD274 protein, human
-
Cd274 protein, mouse
-
Membrane Glycoproteins
-
Peptides